Cabiralizumab - Bristol-Myers Squibb/Five Prime Therapeutics

Drug Profile

Cabiralizumab - Bristol-Myers Squibb/Five Prime Therapeutics

Alternative Names: BMS-986227; Cabiralizumab; FPA-008; ONO-4687

Latest Information Update: 03 Aug 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Five Prime Therapeutics
  • Developer Apexigen; Bristol-Myers Squibb; Five Prime Therapeutics; University of Chicago; Yale University
  • Class Anti-inflammatories; Antineoplastics; Antirheumatics; Immunotherapies; Monoclonal antibodies
  • Mechanism of Action Macrophage colony stimulating factor receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Pigmented villonodular synovitis
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Pancreatic cancer; Pigmented villonodular synovitis
  • Phase I Cancer; Malignant melanoma; Non-small cell lung cancer; Renal cell carcinoma; Solid tumours
  • Discontinued Rheumatoid arthritis

Most Recent Events

  • 01 Aug 2018 New York University School of Medicine plans a phase II trial for Pancreatic Cancer (Inoperable/Unresectable) in August 2018 , (NCT03599362)
  • 14 Jun 2018 Apexigen and Yale Cancer Center enter into a clinical trial collaboration to evaluate APX 005M in combination with cabiralizumab and nivolumab in advanced solid tumours
  • 14 Jun 2018 Bristol-Myers Squibb in collaboration with Apexigen, and Yale Cancer Center plans a phase I/II trial for Malignant melanoma, Non-small Cell Lung Cancer and Renal Cell Carcinoma (Combination therapy, Late-stage disease) (NCT03502330)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top